{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:55:30Z","timestamp":1789977330113,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.vaccine.2017.09.050","type":"journal-article","created":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T10:15:42Z","timestamp":1506161742000},"page":"6160-6165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Trends in pneumococcal meningitis hospitalizations following the introduction of the 13-valent pneumococcal conjugate vaccine in the United States"],"prefix":"10.1016","volume":"35","author":[{"given":"David M.","family":"Jacobs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Yung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie N.H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Shaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.09.050_b0005","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1056\/NEJMoa1005384","article-title":"Bacterial meningitis in the United States, 1998\u20132007","volume":"364","author":"Thigpen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.09.050_b0010","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/j.vaccine.2009.02.063","article-title":"Epidemiology of pneumococcal meningitis hospitalizations in pediatric population in Spain (1998\u20132006)","volume":"27","author":"Gil Prieto","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.09.050_b0015","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1086\/587897","article-title":"Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States","volume":"46","author":"Tsai","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.09.050_b0020","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/INF.0000000000000451","article-title":"Trends of pneumococcal meningitis in children after introduction of the 13-valent pneumococcal conjugate vaccine in France","volume":"33","author":"Levy","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.09.050_b0025","unstructured":"Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49(RR-9):1\u201335."},{"key":"10.1016\/j.vaccine.2017.09.050_b0030","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1542\/peds.113.3.443","article-title":"Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine","volume":"113","author":"Kaplan","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.09.050_b0035","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa0800836","article-title":"Effect of pneumococcal conjugate vaccine on pneumococcal meningitis","volume":"360","author":"Hsu","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.09.050_b0040","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1086\/528996","article-title":"Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005","volume":"197","author":"Moore","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.09.050_b0045","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1001\/jama.297.16.1784","article-title":"Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage","volume":"297","author":"Singleton","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.09.050_b0050","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1086\/524660","article-title":"Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine","volume":"46","author":"Munoz-Almagro","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.09.050_b0055","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1542\/peds.2008-1702","article-title":"Serotype 19A is the most common serotype causing invasive pneumococcal infections in children","volume":"125","author":"Kaplan","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.09.050_b0060","first-page":"1","article-title":"Prevention of pneumococcal disease among infants and children \u2013 use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine \u2013 recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Nuorti","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2017.09.050_b0065","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/INF.0b013e318275614b","article-title":"Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine","volume":"32","author":"Kaplan","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.09.050_b0070","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/cid\/civ368","article-title":"Impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in US Children","volume":"61","author":"Olarte","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.09.050_b0075","unstructured":"Agency of Healthcare Research and Quality. Healthcare cost and utilization project the national inpatient sample. Available at: <https:\/\/www.hcup-us.ahrq.gov\/nisoverview.jsp> [accessed May 1, 2017]."},{"key":"10.1016\/j.vaccine.2017.09.050_b0080","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"10.1016\/j.vaccine.2017.09.050_b0085","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1056\/NEJMoa1209165","article-title":"hospitalizations for pneumonia after a decade of pneumococcal vaccination","volume":"369","author":"Griffin","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.09.050_b0090","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ajic.2016.11.014","article-title":"Prevalence of and outcomes from Staphylococcus aureus pneumonia among hospitalized patients in the United States, 2009\u20132012","volume":"45","author":"Jacobs","year":"2017","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.vaccine.2017.09.050_b0095","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/INF.0b013e3181f4cf69","article-title":"Pneumococcal meningitis in French children before and after the introduction of pneumococcal conjugate vaccine","volume":"30","author":"Levy","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.09.050_b0100","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(14)70032-3","article-title":"Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis","volume":"2","author":"Simonsen","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2017.09.050_b0105","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(14)71081-3","article-title":"Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance","volume":"15","author":"Moore","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.09.050_b0110","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/infdis\/jiu213","article-title":"Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England","volume":"210","author":"Moore","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.09.050_b0115","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Tomczyk","year":"2014","journal-title":"Mmwr-Morbidity Mort Week Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17312987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17312987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T17:36:20Z","timestamp":1530293780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17312987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":23,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0264410X17312987"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.09.050","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in pneumococcal meningitis hospitalizations following the introduction of the 13-valent pneumococcal conjugate vaccine in the United States","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.09.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}